Benefits
Modest Blood Glucose Reduction (T2DM)
Multiple meta-analyses (Allen 2013, Costello 2016) show cinnamon (1-6 g/day) modestly reduces fasting glucose (~10-29 mg/dL) and HbA1c in T2DM patients. Effect is modest and inconsistent across trials. Standard diabetes management (metformin, lifestyle, GLP-1 agonists) remains foundational.
Insulin Sensitivity Improvement
Cinnamon may modestly improve insulin sensitivity via multiple mechanisms — most studied in metabolic syndrome and prediabetes contexts. MHCP compound shown to mimic insulin in vitro. Human translation modest.
Lipid Modest Improvement
Some trials show cinnamon reduces total cholesterol and LDL modestly. Effect inconsistent and substantially weaker than statins or other evidence-based lipid agents.
Antimicrobial / Anti-Fungal
Cinnamaldehyde has broad antimicrobial activity — used in oral care products, food preservation. Topical/oral use modest evidence for oral health.
Anti-Inflammatory / Antioxidant
Procyanidins and other polyphenols in cinnamon have antioxidant activity. Modest anti-inflammatory effects in some markers.
Mechanism of action
Insulin-Mimetic / Sensitizing Effects
MHCP (methyl hydroxychalcone polymer) and other cinnamon compounds activate insulin receptor and downstream signaling — modestly mimicking insulin and improving sensitivity. Animal evidence stronger than human.
Glucose Transporter Effects
Cinnamon may enhance glucose uptake into peripheral tissues via GLUT4 modulation — similar mechanism to exercise and insulin. Modest effect.
Alpha-Glucosidase Inhibition
Cinnamon polyphenols modestly inhibit intestinal alpha-glucosidase — reducing post-prandial glucose spikes. Similar mechanism to acarbose (prescription diabetes drug).
Coumarin Hepatotoxicity (Cassia)
Cassia cinnamon contains COUMARIN at levels (5,000-10,000 mg/kg dry weight) that can cause hepatotoxicity at chronic high doses. Ceylon cinnamon contains <250 mg/kg coumarin. EFSA TDI for coumarin: 0.1 mg/kg body weight/day. Heavy daily Cassia consumption (1-2 tsp+ daily) can exceed safe coumarin intake.
Clinical trials
Meta-analysis of cinnamon (various forms and doses) for T2DM glycemic control.
Pooled across T2DM RCTs.
Cinnamon modestly reduced fasting glucose (~24 mg/dL), total cholesterol, LDL. Effect on HbA1c modest and not consistent. Effect size smaller than metformin or other established diabetes therapies.
Systematic review of cinnamon supplementation for T2DM — Costello et al. 2016.
Pooled across T2DM RCTs.
Modest glycemic effects across trials but high heterogeneity. Some trials positive, others negative. Standard T2DM management primary; cinnamon adjunctive at most.
About this ingredient
Cinnamon is the dried inner bark of Cinnamomum trees. CRITICAL DISTINCTION between species: (1) CEYLON CINNAMON (Cinnamomum verum / 'true cinnamon') — sweeter, lighter color, lower COUMARIN content (<250 mg/kg dry weight); preferred for chronic supplementation; (2) CASSIA CINNAMON (Cinnamomum cassia) — more common in grocery stores and budget supplements; darker, sharper flavor; HIGH COUMARIN content (5,000-10,000 mg/kg dry weight); HEPATOTOXICITY risk at chronic high doses.
KEY ACTIVE COMPOUNDS: cinnamaldehyde (~70-90% of essential oil; primary aromatic/active compound), MHCP (methyl hydroxychalcone polymer; insulin-sensitizing), cinnamic acid, procyanidins (antioxidant flavonoids), eugenol.
EVIDENCE-BASED USES: (1) Modest T2DM glycemic adjunct (Allen 2013; Costello 2016 — modest effect, inconsistent); (2) Insulin sensitivity in metabolic syndrome; (3) Modest lipid effects; (4) Antimicrobial (topical/oral); (5) Culinary use (universally safe in food amounts).
CRITICAL CAUTIONS: (1) COUMARIN HEPATOTOXICITY — CASSIA CINNAMON contains coumarin at levels that can cause liver damage at chronic high doses; EFSA TDI is 0.1 mg/kg body weight/day; 1-2 tsp Cassia daily may exceed this; CEYLON CINNAMON is the preferred form for chronic supplementation due to much lower coumarin; (2) DIABETES MEDICATIONS — additive hypoglycemic effects; monitor blood glucose; consult prescriber if on insulin or sulfonylureas; (3) LIVER DISEASE — AVOID Cassia cinnamon supplementation; Ceylon may be acceptable in moderation; (4) PREGNANCY/LACTATION — culinary amounts safe; high-dose supplementation lacks safety data; AVOID supplementation; cinnamon historically used in some cultures as emmenagogue (menstrual stimulator) — theoretical concern; (5) PRE-SURGERY — discontinue 1-2 weeks before surgery (theoretical bleeding risk); (6) MOUTH/ORAL IRRITATION — particularly with concentrated forms or 'cinnamon challenge' (which is dangerous); (7) ALLERGY / contact dermatitis — possible; (8) DOSE — 1-2 g/day Ceylon cinnamon for general use; up to 6 g/day in trials; standardized extracts (Cinnulin PF®) at 250-500 mg/day; (9) For T2DM, evidence-based pharmacotherapy (metformin, GLP-1 agonists, SGLT2 inhibitors, insulin) and lifestyle (diet, exercise, weight loss) remain foundational; cinnamon is modest adjunct; (10) CINNAMON IDENTIFICATION — Ceylon: lighter color, multiple thin layers in stick form, soft and crumbly; Cassia: darker, single thick layer, hard and dense; verify product specifies CEYLON for chronic supplemental use.